PharmaCyte Biotech, Inc. (PMCB) Corporate Subsidiaries
PharmaCyte Biotech, Inc. (PMCB) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: PMCB
CIK: 1157075
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 04/30
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CBIZ CPAs P.C.
Auditor SinceSince 4/30/2025 12:00:00 AM
Lead Engagement PartnerMichael Cohen
Audit LocationMorristown, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-16 | 2026-10-14 | FORM 8-K | 0001683168-26-007934 | View SEC Doc Filr Page |
| 10-Q | 2026-09-14 | 2026-07-31 | FORM 10-Q FOR JUL 2026 | 0001683168-26-007106 | View SEC Doc Filr Page |
| 10-K | 2026-07-29 | 2026-04-30 | FORM 10-K FOR APRIL 2026 | 0001683168-26-005836 | View SEC Doc Filr Page |
| 4/A | 2026-07-17 | 2026-03-31 | 4/A Filing | 0001683168-26-005622 | View SEC Doc Filr Page |
| 4/A | 2026-07-17 | 2026-03-31 | 4/A Filing | 0001683168-26-005621 | View SEC Doc Filr Page |
| 4/A | 2026-07-17 | 2026-03-31 | 4/A Filing | 0001683168-26-005620 | View SEC Doc Filr Page |
| 4/A | 2026-07-17 | 2026-03-31 | 4/A Filing | 0001683168-26-005619 | View SEC Doc Filr Page |
| 4 | 2026-04-02 | 2026-03-31 | 4 Filing | 0001683168-26-002633 | View SEC Doc Filr Page |
| 4 | 2026-04-02 | 2026-03-31 | 4 Filing | 0001683168-26-002632 | View SEC Doc Filr Page |
| 4 | 2026-04-02 | 2026-03-31 | 4 Filing | 0001683168-26-002631 | View SEC Doc Filr Page |
| 4 | 2026-04-02 | 2026-03-31 | 4 Filing | 0001683168-26-002630 | View SEC Doc Filr Page |
| 8-K | 2026-04-02 | 2026-03-30 | FORM 8-K | 0001683168-26-002613 | View SEC Doc Filr Page |
| 4 | 2026-03-18 | 2026-03-17 | 4 Filing | 0001683168-26-001989 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-03-18 | — | SCHEDULE 13G Filing | 0001683168-26-001988 | View SEC Doc Filr Page |
| 10-Q | 2026-03-17 | 2026-01-31 | FORM 10-Q FOR JAN 2026 | 0001683168-26-001917 | View SEC Doc Filr Page |
| ARS | 2026-03-09 | 2025-04-30 | ANNUAL REPORT | 0001683168-26-001600 | View SEC Doc Filr Page |
| DEF 14A | 2026-03-09 | 2026-03-30 | DEFINITIVE PROXY STATEMENT | 0001683168-26-001593 | View SEC Doc Filr Page |
| PRE 14A | 2026-02-27 | 2026-03-30 | PRELIMINARY PROXY STATEMENT | 0001683168-26-001363 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-02-13 | — | SCHEDULE 13G/A Filing | 0001213900-26-016526 | View SEC Doc Filr Page |
| 4 | 2026-01-07 | 2026-01-05 | 4 Filing | 0001683168-26-000148 | View SEC Doc Filr Page |
| 4 | 2026-01-07 | 2026-01-05 | 4 Filing | 0001683168-26-000147 | View SEC Doc Filr Page |
| 10-Q | 2025-12-18 | 2025-10-31 | FORM 10-Q FOR OCT 2025 | 0001683168-25-009259 | View SEC Doc Filr Page |
| NT 10-Q | 2025-12-15 | 2025-10-31 | EXTENSION | 0001683168-25-009154 | View SEC Doc Filr Page |
| 4 | 2025-12-12 | 2025-04-25 | 4 Filing | 0001683168-25-009116 | View SEC Doc Filr Page |
| 4 | 2025-12-12 | 2025-04-25 | 4 Filing | 0001683168-25-009115 | View SEC Doc Filr Page |